Table 3 Grade 3 and 4 Toxicities observed in 8 patients (54 courses) according to CTCAE 5.0
From: The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma
Toxicity | Grade 3 | Grade 4 | ||
|---|---|---|---|---|
Events (%) | Patients (%) | Events (%) | Patients (%) | |
Blood and lymphatic system disorders | ||||
 Neutropenia | 44 (81.5) | 8 (100.0) | 6 (11.1) | 2 (25.0) |
 Platelet count decreased | 30 (55.6) | 7 (87.5) | 4 (7.4) | 2 (25.0) |
 Anemia | 35 (64.8) | 6 (75.0) | 2 (3.7) | 2 (25.0) |
 Febrile neutropenia | 8 (14.8) | 6 (75.0) | 1 (1.9) | 1 (12.5) |
Gastrointestinal disorders | ||||
 Diarrhea | 40 (74.1) | 8 (100.0) | 4 (7.4) | 2 (25.0) |
 Nausea and vomiting | 36 (66.7) | 8 (100.0) | 1 (1.9) | 1 (12.5) |
 Mucositis oral | 5 (9.3) | 5 (62.5) | 0 (0.0) | 0 (0.0) |
Infections and infestations | ||||
 Abdominal infection | 4 (7.4) | 2 (25.0) | 1 (1.9) | 1 (12.5) |
Metabolism and nutrition disorders | ||||
 Hypokalemia | 21 (38.9) | 8 (100.0) | 2 (3.7) | 2 (25.0) |
 Anorexia | 14 (25.9) | 8 (100.0) | 1 (1.9) | 1 (12.5) |
 Dehydration | 11 (20.4) | 3 (37.5) | 1 (1.9) | 1 (12.5) |
 Weight loss | 12 (22.2) | 3 (37.5) | 0 (0.0) | 0 (0.0) |
Injury, poisoning and procedural complications | ||||
 Pelvic soft tissue necrosis | 0 (0.0) | 0 (0.0) | 1 (1.9) | 1 (12.5) |
 Bladder perforation | 0 (0.0) | 0 (0.0) | 1 (1.9) | 1 (12.5) |